Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

(2015)   Oncotarget

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

(2015) Pasha Apontes et al.   Oncotarget

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

BCCIP is required for the nuclear localization of the p21 protein

(2011) Jinjiang Fan et al.   CELL CYCLE

Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations

(2011) Konstantin J. Dedes et al.   CELL CYCLE

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

(2010) Sherry X. Yang et al.   CANCER BIOLOGY & THERAPY

Analysis of DNA microarray expression data

(2009) Richard Simon   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer

(2008) S. X. Yang et al.   CLINICAL CANCER RESEARCH

A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Toward specific functions of poly(ADP-ribose) polymerase-2

(2008) José Yélamos et al.   TRENDS IN MOLECULAR MEDICINE